EUCTR2020-000043-31-FR
Active, not recruiting
Phase 1
Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients - LIRADIA
Groupe Hospitalier Paris Saint-Joseph0 sites30 target enrollmentStarted: January 20, 2020Last updated:
DrugsLiraglutide
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 30
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •\- Patient aged \= 18 and \<70
- •\- Patient on hemodialysis for more than 6 months
- •\- Type 2 diabetic patient
- •\- Patient with a BMI\> 30 kg / m2 with a Temporary Contraindication for kidney transplant for renal transplant due to overweight by his graft center
- •\- Patient affiliated to a health insurance plan
- •\- French speaking patient
- •\- Patient having given free, informed and written consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •\- Patient with a Temporary Contraindication for kidney transplant for a cause other than overweight
- •\- Patient with personal or family history of thyroid medullary cancer
- •\- Patient with a history of acute or chronic pancreatitis
- •\- Patient who has already had hypersensitivity to liraglutide (or to any other component of the product)
- •\- Patient who has already had a severe digestive intolerance to taking GLP\-1 receptor agonists (such as exenatide or lixisenatide)
- •\- Patient already included in an interventional risk research protocol (RIPH1\)
- •\- Pregnant or lactating woman
- •\- Patient under guardianship or curatorship
- •\- Patient deprived of liberty
Investigators
Similar Trials
Active, not recruiting
Phase 1
Effect of liraglutide for weight management in pubertal adolescent subjects with obesityObesityMedDRA version: 19.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-004353-14-BEovo Nordisk A/S228
Active, not recruiting
Phase 1
Effect of liraglutide for weight management in pubertal adolescent subjects with obesityObesityMedDRA version: 19.1 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-004353-14-SEovo Nordisk A/S228
Active, not recruiting
Phase 1
Effect of liraglutide for weight management in children with Prader-Willi SyndromeObesity(Prader-Willi syndrome)MedDRA version: 18.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-004415-37-FRovo Nordisk A/S60
Active, not recruiting
Phase 1
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-ITovo Nordisk A/S56
Active, not recruiting
Phase 1
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-NLovo Nordisk A/S60